RT Journal Article
T1 Assessment of a Potential Synergistic Effect of Souvenaid® in Mild Alzheimer's Disease Patients on Treatment with Acetylcholinesterase Inhibitors: An Observational, Non-Interventional Study.
A1 Viñuela, Félix
A1 Barro, Angeles
K1 Alzheimer’s disease
K1 Fortasyn Connect
K1 cognitive dysfunction
K1 observational study
K1 pragmatic clinical trials
AB We evaluated the efficacy and safety of Souvenaid (a multinutrient supplement) in patients with mild Alzheimer's disease (AD) in real clinical practice and assessed a potential synergistic effect of acetylcholinesterase (AChE) inhibitors. Clinical Dementia Rating (CDR) scale was evaluated after six months follow-up. Patients were divided into 4 groups according to the treatment they received: Souvenaid + AChE inhibitors (n = 23); only Souvenaid (n = 8); only AChE inhibitors (n = 7); no treatment (n = 16). The Souvenaid + AChE inhibitors and Souvenaid alone groups were associated with significantly lower increases in CDR per month than the AChE inhibitors or no treatment ones. The efficacy of Souvenaid + AChE inhibitors tended to be higher than Souvenaid alone.
YR 2021
FD 2021
LK http://hdl.handle.net/10668/17326
UL http://hdl.handle.net/10668/17326
LA en
DS RISalud
RD Apr 12, 2025